POINT Biopharma Global, Inc. (PNT)
|Net Income (ttm)||-72.27M|
|Day's Range||7.87 - 8.50|
|52-Week Range||4.25 - 11.72|
|Price Target||19.64 (+138.6%)|
|Earnings Date||Aug 12, 2022|
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting prod... [Read more...]
Financial PerformanceFinancial Statements
According to 9 analysts, the average rating for PNT stock is "Buy." The 12-month stock price forecast is 19.64, which is an increase of 138.64% from the latest price.
Additional data from the lead-in of PNT2002's SPLASH trial on track for fall 2022 release
POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on Au...
The event will prepare investors for the release of SPLASH's lead-in cohort efficacy data later this year by providing an overview of SPLASH's trial design.
INDIANAPOLIS, July 06, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing...
Mr. Horvath will lead the commercialization of POINT's pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer Radioligan...
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004's Phase 1 therapeutic trial using 68 Ga-PNT6555 for imaging and 177 Lu-PNT6555 for therapy
POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled.
Clinical doses continue to be manufactured and shipped from the Company's Indianapolis, Indiana facility Clinical doses continue to be manufactured and shipped from the Company's Indianapolis, Indiana f...
POINT's PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68 Ga-PNT6555 for imaging and 177 Lu-PNT6555 for therapy is planned for summe...
Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial
POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption
POINT's industry-leading radioisotope supply chain enabled company to avoid delays POINT's industry-leading radioisotope supply chain enabled company to avoid delays
Learn what “PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied” means in the context of radiopharmaceuticals
POINT Biopharma (PNT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH trial...
Dosimetry data demonstrated PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied
INDIANAPOLIS, Feb. 17, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing...
Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022
Company's radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com
POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development
Dr. Vincent brings more than 25 years of pharma business development experience along with deep technical expertise including drug development relating to oncology/immuno-oncology, inflammatory, and aut...
POINT Biopharma adds a COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes
Justyna Kelly promoted to COO, Dr. Robin Hallett promoted to VP, Discovery and Translational Sciences, Dr. Sherin Al-Safadi to join as VP Medical Affairs, and Michael Gottlieb (CCO) to depart the Compan...
POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)
POINT adds key technology to accelerate in-house no-carrier-added Lu-177 production POINT adds key technology to accelerate in-house no-carrier-added Lu-177 production
POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations
Initiated randomization phase of Phase 3 SPLASH study of PNT2002 in patients with metastatic castration-resistant prostate cancer (mCRPC)
Supply agreement enables development of POINT's next-generation Ac-225-based radioligand therapies. Supply agreement enables development of POINT's next-generation Ac-225-based radioligand therapies.
POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement Enabling North American Production of n.c.a. Lu-177
POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations on Dec 6, 2021 – register online at https://hub.pointbiopharma.com/d...
ARTMS Inc. Announces Health Canada Submission for Ga-68 Production and Tri-party Collaboration to Advance Ga-68 Imagi...
BURNABY, British Columbia--(BUSINESS WIRE)--ARTMS Inc. (ARTMS), the global leader in developing and commercializing novel products enabling cyclotron production of the world's most needed medical radioi...
Point Biopharma Global Inc (NASDAQ: PNT) has additional preclinical data from its fibroblast activation protein-alpha (FAP-alpha) inhibitor program, PNT2004. The new data demonstrate rapid and persiste...